Skip to main content

Treatment Clinical Trials for Lymphoma

Review the lymphoma treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 456

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Status: Active
Location: 367 locations
Testing Early Treatment for Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Status: Active
Location: 489 locations
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Status: Active
Location: 242 locations
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients with High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Status: Active
Location: 198 locations
Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Active
Location: 137 locations
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients with Peripheral T-cell Lymphoma who Achieved a Complete Response at the End of the Initial Chemotherapy
Status: Active
Location: 130 locations
Testing the use of Daratumumab-Hyaluronidase in Persistent or Recurrent T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) following Treatment with Chemotherapy
Status: Active
Location: 123 locations
A Phase 2 Study Adding the Drugs Tazemetostat or Zanubrutinib to Usual Treatment for People with Large B-Cell Lymphoma that Returned or Did Not Respond to Earlier Treatment
Status: Active
Location: 105 locations
Testing Drug Treatments after CAR T-cell Therapy in Patients with Diffuse Large B-cell Lymphoma That Has Come Back or Not Responded to Treatment
Status: Active
Location: 85 locations
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients with Relapsed and/or Refractory Aggressive B-cell Lymphoma
Status: Active
Location: 65 locations
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Status: Active
Location: 48 locations
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients with Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
Status: Active
Location: 33 locations
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
Status: Active
Location: 27 locations
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Status: Active
Location: 23 locations
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma
Status: Active
Location: 20 locations
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Status: Active
Location: 19 locations
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Status: Active
Location: 19 locations
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Status: Active
Location: 20 locations
DALY II USA/ MB-CART2019.1 for DLBCL
Status: Active
Location: 18 locations
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Status: Active
Location: 18 locations
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (“EPOCH”) for Adult T-Cell Leukemia-Lymphoma (ATLL)
Status: Active
Location: 19 locations
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Status: Active
Location: 17 locations
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Status: Active
Location: 17 locations
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Status: Active
Location: 18 locations
Brentuximab Vedotin in Combination with Pembrolizumab for the Treatment of Patients with CD30 Positive T-cell Non-Hodgkin Lymphoma
Status: Active
Location: 16 locations